Hansa Biopharma (HNSA) Corporate presentation summary

Technology platform and product overview

• Proprietary IgG-cleaving enzyme platform enables rapid and targeted reduction of IgG antibodies, facilitating treatments for transplantation, gene therapy, and autoimmune diseases.

• Imlifidase achieves >95% IgG reduction within 2-6 hours and has been tested in 11 clinical programs.

• Next-generation enzyme HNSA-5487 targets Guillain-Barré Syndrome (GBS) with late-stage clinical development planned.

Transplantation and desensitization market

• Addresses high unmet need for highly sensitized kidney transplant patients, with no approved US therapies and significant waitlist challenges.

• IDEFIRIX conditionally approved in the EU, generating ~204.7 MSEK (~$22.8m) in 2025 sales and available in 23+ European markets.

• US BLA accepted in February 2026, with PDUFA date set for December 19, 2026.

• Successful US Confides Phase 3 study showed significant improvement in eGFR and dialysis dependency, with good safety profile.

• Long-term follow-up demonstrated 82% five-year graft survival and 90% patient survival.

Commercialization and financial highlights

• Robust US commercialization strategy with experienced team and focus on market access, pricing, and reimbursement.

• IDEFIRIX sales grew 46% in 2025, with ~70% repeat utilization and 117 clinics equipped.

• Ended 2025 with 701.1 MSEK (~$78M) in cash, supported by a $30M convertible note in Q1 2026.